echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 12 pharmaceutical stocks daily limit, belonging to traditional Chinese medicine, pharmaceutical business and other sectors

    12 pharmaceutical stocks daily limit, belonging to traditional Chinese medicine, pharmaceutical business and other sectors

    • Last Update: 2022-04-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [Pharmaceutical Network Pharmaceutical Stock Market] As of the close of March 7, there were 12 stocks in the pharmaceutical and biological sector, including Dali Pharmaceutical, Dajia Weikang, China Pharmaceutical, First Pharmaceutical, Gongtong Pharmaceutical, Haichen Pharmaceutical, etc.
    The industry mainly focuses on traditional Chinese medicine, pharmaceutical business, chemical raw materials, medical services and other sub-sectors
    .

    As of the close on March 7, Gongtong Pharmaceutical closed at 60.
    82 yuan, a change of 20.
    01%, a turnover rate of 58.
    79%, and a turnover of 963 million yuan
    .

    The company announced on the evening of March 7 that the stock trading of Hubei Gongtong Pharmaceutical Co.
    , Ltd.
    had a cumulative deviation of more than 30% of the daily closing price increase within two consecutive trading days (March 4, 2022, March 7, 2022)
    .

    After verification, the company, the controlling shareholder and the actual controller do not have any major events that should be disclosed but have not been disclosed, nor do they have major events in the planning stage
    .

       According to the data, Gongtong Pharmaceutical is a company specializing in the research and development, production and sales of steroid drug raw materials.
    The main products are the starting materials and intermediates required for the production of steroid drugs
    .

       Dali Pharmaceutical Dali Pharmaceutical closed at 11.
    09 yuan on March 7, an increase of 10.
    02%, a turnover rate of 11.
    66%, and a turnover of 275 million
    .

       The company issued an announcement in the evening that the company's stock on March 4, 2022, and March 7, 2022, the closing price of the company's stock has increased by more than 20% for two consecutive trading days, which is an abnormal fluctuation in stock trading
    .

    The company's stock price will increase by the limit for 4 consecutive trading days on March 2, 2022, March 3, 2022, March 4, 2022, and March 7, 2022, and the deviation of the closing price increase for 4 consecutive trading days is accumulatively 43.
    42%
    .

    After the company's self-inspection and written consultation with the controlling shareholder and actual controller, as of the disclosure date of this announcement, there is no material information that should be disclosed but has not been disclosed
    .

       According to the data, Dali Pharmaceutical's main business includes the production and sales of Chinese and Western medicine injections
    .

       Dajia Weikang As the concept of assisted reproduction continues to strengthen, Dajia Weikang also opened the daily limit on March 7, and the daily closed at 36.
    44 yuan, an increase of 19.
    99%, a turnover rate of 12.
    29%, and a turnover of 219 million
    .

       On the news, Dajia Weikang stated on the investor interaction platform on March 7 that the company is mainly engaged in the distribution and retail business of medicines, biological products, medical devices and other products.
    Store layout, as of September 30, 2021, the number of professional pharmacies in the company has tripled; as a regional distribution company, the company operates tens of thousands of pharmaceutical products, and is one of the main distributors of upstream pharmaceutical companies in Hunan Province.
    A certain product has little impact on the company's revenue ratio.
    Investors are advised to make decisions carefully and pay attention to preventing investment risks
    .

       Affected by the rumors that Sinopharm and Pfizer have reached a cooperation on Paxlovid, Sinopharm has won the fourth consecutive board from March 2 to March 7
    .

    As of the close on March 7, China Pharmaceutical closed at 16.
    25 yuan, an increase of 10.
    02%, a turnover rate of 1.
    05%, and a turnover of 183 million
    .

       On March 4, Sinopharm issued an announcement on abnormal fluctuations in stock trading, saying that after verification, the above-mentioned rumors are currently being communicated and negotiated, but there are still uncertainties about the specific terms of the agreement and whether it can be successfully signed
    .

       On March 7, the relevant person in charge of Pfizer told the media that the commercialization of the Paxlovid drug has not yet been confirmed, whether it is the cooperation with China Pharmaceuticals or the hospital's emergency department
    .

       First Medicine The trading public information released by the Shanghai and Shenzhen Stock Exchanges on March 07, 2022 shows that First Medicine was listed on the list because it became a security with a deviation of 7% on the day and a cumulative 20% deviation of the closing price within three consecutive trading days.

    .

    As of the close on March 7, First Medicine closed at 12.
    71 yuan, an increase of 10.
    04%, a turnover rate of 11.
    45%, and a turnover of 310 million
    .

       According to the data, First Medicine is mainly engaged in the retail and wholesale business of pharmaceuticals
    .

       Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.